A Rare but Serious Side Effect: Cancer Immunotherapy and Type 1 Diabetes

Immune checkpoint inhibitors are a newer class of cancer drugs designed to remove the 'brakes' on the immune system, allowing it to fight tumor cells more effectively. They've proven valuable in treating many cancers, but they come with a trade-off: by activating the immune system broadly, they can sometimes cause it to attack the body's own healthy tissues. These unintended attacks are called immune-related adverse events, or irAEs.

The pancreas is an especially vulnerable organ during immune checkpoint inhibitor treatment because it performs two very different jobs: it produces digestive enzymes (exocrine function) and regulates blood sugar through insulin production (endocrine function). When the immune system attacks the pancreas due to an ICI, the inflammation can affect either function or both at once.

In most cases, this shows up as acute pancreatitis alone or new-onset diabetes alone. But in extremely rare cases, both conditions strike simultaneously—a medical emergency known as ICI-induced acute pancreatitis concurrent with fulminant type 1 diabetes.

A 59-year-old patient with tongue cancer received an immune checkpoint inhibitor called toripalimab combined with chemotherapy. Just seven days after starting treatment, he developed severe nausea, vomiting, and confusion. Emergency blood tests revealed dangerously high blood sugar (17.4 mmol/L), severe diabetic ketoacidosis (a life-threatening condition where the blood becomes too acidic), and elevated pancreatic enzymes indicating inflammation. A CT scan confirmed acute pancreatitis, while blood tests showed his insulin-producing cells had essentially stopped working.

The patient's glycated hemoglobin (HbA1c)—which reflects blood sugar control over months—was normal before treatment, and pancreatic autoantibodies were negative, confirming this was a newly triggered condition, not an underlying diabetes that had gone undetected.

This combination is so rare and unfamiliar that it's easy to miss in clinical practice, putting patients at serious risk. The case described here was life-threatening within days of symptom onset. However, immediate recognition and treatment—stopping the ICI drug, providing supportive care to rest the pancreas, managing fluids and electrolytes, and starting intensive insulin therapy—can save lives.

For anyone undergoing treatment with an immune checkpoint inhibitor, awareness of these symptoms is important: rapid onset of nausea, vomiting, confusion, extreme thirst, frequent urination, or abdominal pain warrant emergency evaluation. While this side effect is genuinely rare, it's not impossible, and quick action makes the difference.

Source: Frontiers in immunology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.